CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 222 enrolled
Drug / intervention
VELCADE Administered by subcutaneous injection +1 moredrug
Likely dose
VELCADE Administered by subcutaneous injection 1.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00722566
NCT00722566Phase 3Completed
CompareCT.gov

An Open-Label Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma

Millennium Pharmaceuticals, Inc.·interventional·Posted Jul 25, 2008·Updated Oct 10, 2011

In Brief

A Phase 3 clinical trial evaluating VELCADE Administered by subcutaneous injection and VELCADE Administered by intravenous infusion for Multiple Myeloma. Completed, enrolled 222 participants across 3 sites in 3 countries.

Detailed Summary

Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBelgium, France, Germany
CollaboratorsJohnson & Johnson Pharmaceutical Research & Development, L.L.C.

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 25, 2008
Enrollment StartJul 1, 2008
Primary CompletionAug 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.9 years ago

Interventions

VELCADE Administered by subcutaneous injectiondrug

Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle

VELCADE Administered by intravenous infusiondrug

Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.